Afterward, to assess whether Bre–Ved–ZA ADC can induce the activation of Vδ2 T-cells via ZA delivery, purified T-lymphocytes (>95% pure CD2+CD3+) were added to monocytes, in the absence or presence of HL-cells, to mimic the tumor microenvironment, at the ratio of 10:1 (105 T-cells: 104 HL-cells and 104 Mo), with 2 μg/mL of Bre–Ved–ZA or Bre–Ved and IL-2 (30 IU/10 ng/mL) was added after 24 h of culture. The gene discussed is CD2; the disease is neoplasm.